Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Subscribe to Pharma in Focus

Sign Up Now

Pharma in Focus is considered essential daily reading in the Australian and NZ pharma industry.

In production for 14 years, it is emailed twice daily to more than 11,000 pharma industry professionals throughout Australia and NZ.

For just $454.50 a year (plus GST) Pharma in Focus puts you ahead of the game by delivering:

  • Key Aussie & NZ pharma news every working day
  • Daily in-depth features covering all aspects of pharma from drug approvals to employment issues
  • Full coverage and analysis of PBAC, PBS and TGA decisions
  • Ten survey-based white papers per year (total value $1500)

New to Pharma in Focus? Sign up below for your FREE two week trial.

Time to subscribe? Sign up below for your 12 month subscription.

Need multiple licenses? We have great corporate rates. Contact our friendly subscription managers on 02 9939 1881 or for our latest prices.

3 Simple Steps

1 Fill in your details below and submit

2 Make your subscription choice

3 Make your payment choice (Credit Card, Direct Deposit or Cheque)

Approvals Action
MSD's new anti-infective registered
MSD's new treatment for clostridium difficile infection has been registered on the ARTG after consideration by the PBAC earlier this month.
Pipeline Monitor
Bumper week for AZ
AstraZeneca has registered regulatory wins for cancer drug Faslodex and new asthma biologic Fasenra in a busy week for the Anglo-Swedish company.
Why health bureaucrats need to do yoga
As health bureaucrats mull over a unique funding deal slapped down on the table by a drug sponsor looking to find a new path to reimbursement, they may find learning a few yoga moves useful.